The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.
The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.
Researchers at MD Anderson Cancer Center have demonstrated that therapeutically restoring ‘youthful’ levels of a specific subunit of the telomerase enzyme can significantly reduce the signs and symptoms of aging in preclinical models.
The Institute for Data Science in Oncology at MD Anderson Cancer Center has established an internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.
Susan BullmanXi ChenSusan Bullman and Xi Chen were named associate members at the James P. Allison Institute at MD Anderson Cancer Center.
According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.
The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia without a subsequent stem cell transplant, according to results from the phase Ib/II FELIX clinical trial presented by Elias Jabbour, professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia. Results from the retrospective multi-center analysis were presented by Alexandre Bazinet, assistant professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
